Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $122.64 Consensus Price Target from Analysts

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has been assigned a consensus rating of “Moderate Buy” from the twenty-three ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and twenty have given a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $124.4783.

A number of brokerages recently issued reports on KYMR. Guggenheim raised their price objective on Kymera Therapeutics from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Royal Bank Of Canada lowered shares of Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and increased their target price for the stock from $106.00 to $115.00 in a research note on Monday, July 13th. Brookline Capital Markets reiterated a “buy” rating on shares of Kymera Therapeutics in a research report on Monday, June 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Friday, July 17th. Finally, Bank of America upped their price objective on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th.

Kymera Therapeutics Stock Performance

Shares of Kymera Therapeutics stock opened at $103.40 on Monday. The stock has a 50 day moving average of $98.92 and a 200 day moving average of $87.77. The firm has a market capitalization of $8.51 billion, a price-to-earnings ratio of -28.96 and a beta of 1.95. Kymera Therapeutics has a fifty-two week low of $36.65 and a fifty-two week high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. The company had revenue of $34.37 million for the quarter, compared to the consensus estimate of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.82) earnings per share. Analysts forecast that Kymera Therapeutics will post -3.29 EPS for the current year.

Insider Buying and Selling

In related news, insider Noah Goodman sold 3,389 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $114.29, for a total value of $387,328.81. Following the sale, the insider owned 47,179 shares in the company, valued at approximately $5,392,087.91. The trade was a 6.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bruce Booth sold 31,283 shares of the stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $109.48, for a total value of $3,424,862.84. Following the transaction, the director directly owned 461,794 shares in the company, valued at approximately $50,557,207.12. The trade was a 6.34% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 3,607,813 shares of company stock valued at $387,818,004 over the last quarter. 15.98% of the stock is owned by corporate insiders.

Institutional Trading of Kymera Therapeutics

Hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC grew its holdings in shares of Kymera Therapeutics by 27.5% in the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock valued at $52,000 after purchasing an additional 98 shares in the last quarter. US Bancorp DE boosted its position in Kymera Therapeutics by 9.8% in the 3rd quarter. US Bancorp DE now owns 1,865 shares of the company’s stock valued at $106,000 after buying an additional 166 shares during the period. Glenmede Trust Co. NA grew its stake in shares of Kymera Therapeutics by 3.6% in the first quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock worth $565,000 after acquiring an additional 235 shares in the last quarter. Cetera Investment Advisers increased its position in shares of Kymera Therapeutics by 7.5% during the first quarter. Cetera Investment Advisers now owns 3,602 shares of the company’s stock worth $300,000 after acquiring an additional 252 shares during the period. Finally, Larson Financial Group LLC raised its stake in shares of Kymera Therapeutics by 36.9% in the fourth quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock valued at $83,000 after acquiring an additional 287 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.